FR14C0074I2 - Derives du benzol substitues par un glucopyranosyle,, medicaments renfermant ces composes, leur utilisation et leur procede de production - Google Patents

Derives du benzol substitues par un glucopyranosyle,, medicaments renfermant ces composes, leur utilisation et leur procede de production

Info

Publication number
FR14C0074I2
FR14C0074I2 FR14C0074C FR14C0074C FR14C0074I2 FR 14C0074 I2 FR14C0074 I2 FR 14C0074I2 FR 14C0074 C FR14C0074 C FR 14C0074C FR 14C0074 C FR14C0074 C FR 14C0074C FR 14C0074 I2 FR14C0074 I2 FR 14C0074I2
Authority
FR
France
Prior art keywords
glucopyranosyl
compounds
production
medicaments containing
derivatives substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0074C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0074(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102004012676A external-priority patent/DE102004012676A1/de
Priority claimed from DE102004040168A external-priority patent/DE102004040168A1/de
Priority claimed from DE102004061145A external-priority patent/DE102004061145A1/de
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of FR14C0074I1 publication Critical patent/FR14C0074I1/fr
Application granted granted Critical
Publication of FR14C0074I2 publication Critical patent/FR14C0074I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
FR14C0074C 2004-03-16 2014-09-24 Derives du benzol substitues par un glucopyranosyle,, medicaments renfermant ces composes, leur utilisation et leur procede de production Active FR14C0074I2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE102004012676A DE102004012676A1 (de) 2004-03-16 2004-03-16 Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004040168A DE102004040168A1 (de) 2004-08-18 2004-08-18 Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004061145A DE102004061145A1 (de) 2004-12-16 2004-12-16 Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP05002628 2005-02-09
EP05715979A EP1730131B1 (de) 2004-03-16 2005-03-11 Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
PCT/EP2005/002618 WO2005092877A1 (de) 2004-03-16 2005-03-11 Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
FR14C0074I1 FR14C0074I1 (cs) 2014-10-31
FR14C0074I2 true FR14C0074I2 (fr) 2015-05-22

Family

ID=34962236

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0074C Active FR14C0074I2 (fr) 2004-03-16 2014-09-24 Derives du benzol substitues par un glucopyranosyle,, medicaments renfermant ces composes, leur utilisation et leur procede de production

Country Status (33)

Country Link
US (6) US7579449B2 (cs)
EP (4) EP2360165A3 (cs)
JP (3) JP4181605B2 (cs)
KR (2) KR20120007088A (cs)
CN (4) CN103435581B (cs)
AR (3) AR048041A1 (cs)
AT (1) ATE557013T1 (cs)
AU (1) AU2005225511C1 (cs)
BE (1) BE2014C064I2 (cs)
BR (1) BRPI0508830B8 (cs)
CA (1) CA2557801C (cs)
CY (2) CY1112948T1 (cs)
DK (1) DK1730131T3 (cs)
EA (1) EA011158B1 (cs)
EC (1) ECSP066855A (cs)
ES (1) ES2387881T3 (cs)
FR (1) FR14C0074I2 (cs)
HR (1) HRP20120627T1 (cs)
HU (1) HUS1400056I1 (cs)
IL (2) IL218714A (cs)
LT (1) LTC1730131I2 (cs)
LU (1) LU92555I2 (cs)
ME (1) ME01422B (cs)
MY (1) MY151336A (cs)
NO (3) NO335264B1 (cs)
NZ (1) NZ550464A (cs)
PL (1) PL1730131T3 (cs)
PT (1) PT1730131E (cs)
RS (1) RS52365B (cs)
SG (1) SG151271A1 (cs)
SI (1) SI1730131T1 (cs)
TW (1) TWI323264B (cs)
WO (1) WO2005092877A1 (cs)

Families Citing this family (253)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP2360165A3 (de) * 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7393836B2 (en) * 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1773800A1 (de) * 2004-07-27 2007-04-18 Boehringer Ingelheim International GmbH D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE102004048388A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
WO2006064033A2 (en) * 2004-12-16 2006-06-22 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
WO2006089872A1 (en) * 2005-02-23 2006-08-31 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
ATE453656T1 (de) 2005-04-15 2010-01-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) * 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
ES2346347T3 (es) 2005-07-27 2010-10-14 Boehringer Ingelheim International Gmbh Derivados de ((hetero)cicloalquiletinil-bencil)-benceno y su uso como inhibidores del cotransportador de glucosa dependiente de sodio (sglt).
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
ATE484499T1 (de) * 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
CN101238112A (zh) * 2005-09-08 2008-08-06 贝林格尔·英格海姆国际有限公司 1-氯-4-(β-D-吡喃葡萄糖-1-基)-2-(4-乙炔基-苄基)-苯的晶形、其制备方法及其用于制备药物中的用途
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
ES2369016T3 (es) * 2006-02-15 2011-11-24 Boehringer Ingelheim International Gmbh Derivados de benzonitrilo sustituidos por glucopiranosilo, composiciones farmacéuticas que contienen tales tipos de compuestos, su uso y procedimiento para su fabricación.
AU2007216452A1 (en) * 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
TW200812995A (en) 2006-05-19 2008-03-16 Taisho Pharmaceutical Co Ltd C-phenyl glycitol compound
US7803778B2 (en) * 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
CA2656847A1 (en) * 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
EA015964B1 (ru) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
KR20090066289A (ko) 2006-09-08 2009-06-23 로드아일랜드하스피틀 알코올 유발성 뇌 질환의 치료, 예방 및 역행
US7858587B2 (en) * 2006-09-21 2010-12-28 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
CN101522699A (zh) 2006-10-13 2009-09-02 中外制药株式会社 硫葡萄糖螺缩酮衍生物、及其作为糖尿病治疗药的应用
EP2086991A1 (en) 2006-10-27 2009-08-12 Boehringer Ingelheim International GmbH CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
US7879806B2 (en) 2006-11-06 2011-02-01 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture
EP2081569A2 (en) * 2006-11-09 2009-07-29 Boehringer Ingelheim International GmbH Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
MX2009006444A (es) 2006-12-21 2009-06-26 Astellas Pharma Inc Metodo para producir derivado de c-glucosido e intermediario sintetico del mismo.
US7795228B2 (en) * 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use
EP2382972A1 (en) 2007-01-26 2011-11-02 Boehringer Ingelheim International GmbH Methods for preventing and treating neurodegenerative disorders
WO2008101938A1 (en) * 2007-02-21 2008-08-28 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
JP2010519273A (ja) * 2007-02-21 2010-06-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 四置換グルコピラノシル化ベンゼン誘導体、このような化合物を含む薬物、それらの使用及びそれらの製造方法
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
CN104803957A (zh) * 2007-04-02 2015-07-29 泰拉科斯有限公司 苄基化糖苷衍生物及其用法
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
WO2009026537A1 (en) 2007-08-23 2009-02-26 Theracos, Inc. Benzylbenzene derivatives and methods of use
CN101801371B (zh) * 2007-09-10 2012-11-28 詹森药业有限公司 可用作sglt抑制剂的化合物的制备方法
JP5498392B2 (ja) * 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
ES2541141T3 (es) * 2008-01-31 2015-07-16 Astellas Pharma Inc. Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0913129A2 (pt) 2008-05-22 2016-01-05 Bristol Myers Squibb Co método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
WO2010009243A1 (en) 2008-07-15 2010-01-21 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
PT2324002T (pt) 2008-08-22 2016-11-09 Theracos Sub Llc Processos para a preparação de inibidores de sglt2
MX2011002166A (es) * 2008-08-28 2011-04-07 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
MX345494B (es) * 2009-02-13 2017-02-02 Boehringer Ingelheim Int Gmbh * Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, dosificación farmacéutica de la misma, procesos para su preparación y usos de la misma para el control glucemico mejorado en un paciente.
MY161472A (en) * 2009-02-13 2017-04-14 Boehringer Ingelheim Int Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
PL2395983T3 (pl) * 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
PT2414363E (pt) * 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR101532412B1 (ko) 2009-07-10 2015-06-29 얀센 파마슈티카 엔.브이. 1-(β-Ｄ-글루코피라노실)-4-메틸-3-(5-(4-플루오로페닐)-2-티에닐메틸) 벤젠의 결정화 방법
AR077859A1 (es) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
WO2011035250A1 (en) 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
HUE029381T2 (en) 2009-09-30 2017-02-28 Boehringer Ingelheim Int Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
BR112012007085B8 (pt) 2009-09-30 2021-05-25 Boehringer Ingelheim Int processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
SG10201500258WA (en) * 2009-10-14 2015-03-30 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
NZ599945A (en) 2009-11-02 2014-05-30 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP2368552A1 (en) 2010-03-25 2011-09-28 Boehringer Ingelheim Vetmedica GmbH 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
US20140088027A1 (en) * 2010-03-30 2014-03-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
LT2568988T (lt) 2010-05-11 2016-09-12 Janssen Pharmaceutica, N.V. Farmacinės kompozicijos, apimančios 1-(beta-d-gliukopiranozil)-2-tienilmetilbenzeno darinius kaip sglt inhibitorius
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
UA110347C2 (uk) 2010-08-12 2015-12-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
CN102453026A (zh) * 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
BR112013010021A2 (pt) 2010-11-02 2019-09-24 Boehringer Ingelheim Int combinações farmacêuticas para o tratamento de distúrbios metabólicos.
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
WO2012109996A1 (zh) 2011-02-18 2012-08-23 上海璎黎科技有限公司 一种芳基糖苷类化合物及其制备方法和应用
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
EA201301354A1 (ru) * 2011-06-03 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013000275A1 (zh) 2011-06-25 2013-01-03 山东轩竹医药科技有限公司 C-糖苷衍生物
US20130035298A1 (en) 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
RU2500407C2 (ru) * 2012-02-20 2013-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Средство, обладающее мочегонным действием
RU2517091C2 (ru) * 2012-02-20 2014-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации) Средство, обладающее мочегонным действием
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2013152476A1 (en) 2012-04-10 2013-10-17 Theracos, Inc. Process for the preparation of benzylbenzene sglt2 inhibitors
JP2015516404A (ja) 2012-05-09 2015-06-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝疾患の処置のための合剤
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9145434B2 (en) * 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN103864737B (zh) * 2012-12-17 2016-08-17 天津药物研究院 含脱氧葡萄糖结构的苯基c-葡萄糖苷衍生物及其制备方法和用途
CN103910769B (zh) 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
PT3466431T (pt) * 2013-03-14 2024-01-26 Msd Int Gmbh Formas cristalinas e métodos para preparação de inibidores de sglt2
EP4245765A3 (en) 2013-04-04 2024-03-20 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR102309654B1 (ko) 2013-04-18 2021-10-08 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
CN104250272B (zh) * 2013-06-27 2018-10-09 上海方楠生物科技有限公司 一种利用微反应器制备列净类药物中间体的方法
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
EP3063116A1 (en) * 2013-10-31 2016-09-07 Sun Pharmaceutical Industries Ltd Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
ES2969764T3 (es) 2013-12-17 2024-05-22 Boehringer Ingelheim Vetmedica Gmbh Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos
WO2015101916A1 (en) 2013-12-30 2015-07-09 Mylan Laboratories Ltd. Process for the preparation of empagliflozin
CN104761522B (zh) * 2014-01-03 2017-02-15 山东轩竹医药科技有限公司 光学纯的苄基‑4‑氯苯基的c‑糖苷衍生物
US9315438B2 (en) 2014-01-03 2016-04-19 Xuanzhu Pharma Co., Ltd Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
EP2891654B1 (en) 2014-01-03 2016-06-22 Xuanzhu Pharma Co., Ltd. Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus)
CN115282284A (zh) * 2014-01-23 2022-11-04 勃林格殷格翰动物保健有限公司 犬科动物中代谢紊乱的治疗
CN103739581B (zh) * 2014-01-23 2016-11-23 中国药科大学 C-芳基葡萄糖苷sglt2抑制剂
CN104861002A (zh) * 2014-02-26 2015-08-26 天津药物研究院 含3,6-脱水葡萄糖结构的苯基c-葡萄糖苷衍生物及其制备方法和用途
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
ES2811261T3 (es) 2014-04-01 2021-03-11 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabólicos en animales equinos
CN105001213B (zh) * 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
HUE068152T2 (hu) 2014-09-25 2024-12-28 Boehringer Ingelheim Vetmedica Gmbh SGLT2-gátlók és dopamin agonisták kombinációs kezelése anyagcserezavarok megelõzésére lófélékben
TWI740546B (zh) * 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
DE102014018230B4 (de) * 2014-12-04 2016-10-27 Mann + Hummel Gmbh Akkumulator-Anordnung für ein Fahrzeug
EP3256482B1 (en) * 2015-02-09 2019-11-27 Indoco Remedies Limited Process for the preparation of sglt inhibitor compounds
CZ2015110A3 (cs) 2015-02-18 2016-08-31 Zentiva, K.S. Pevné formy empagliflozinu
HK1249847A1 (zh) 2015-03-09 2018-11-16 Intekrin Therapeutics, Inc. 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
CZ2015279A3 (cs) 2015-04-24 2016-11-02 Zentiva, K.S. Pevné formy amorfního empagliflozinu
WO2016174155A1 (en) 2015-04-30 2016-11-03 Boehringer Ingelheim International Gmbh Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
CN106336403A (zh) * 2015-07-14 2017-01-18 江苏豪森药业集团有限公司 依帕列净的工业制备方法
MX389367B (es) 2015-08-27 2025-03-20 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas liquidas que comprenden inhibidores de sglt-2.
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
ES2896101T3 (es) 2015-09-15 2022-02-23 Laurus Labs Ltd Cocristales de inhibidores de SGLT2, procedimiento para su preparación y composiciones farmacéuticas de los mismos
HRP20220355T1 (hr) 2015-09-16 2022-05-13 Gilead Sciences, Inc. Postupci za liječenje infekcija coronaviridae
EP3362055B1 (en) 2015-10-15 2023-01-18 Boehringer Ingelheim International GmbH Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
RU2614142C1 (ru) * 2016-01-14 2017-03-23 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский политехнический университет" Способ получения мета-хлорбензгидриламина - полупродукта в синтезе противосудорожного препарата галодиф
WO2017130217A1 (en) * 2016-01-27 2017-08-03 Msn Laboratories Private Limited The present invention relates to process for the preparation of d-glucitol, 1,5- anhydro-1-c-[4-chloro-3-[[4-[[(3s)-tetrahydro-3-furanyl] oxy]phenyl] methyl]phenyl]-, (1s) and its crystalline forms thereof.
WO2017141202A1 (en) * 2016-02-17 2017-08-24 Lupin Limited Complex of sglt2 inhibitor and process for preparation thereof
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN107641139A (zh) * 2016-07-22 2018-01-30 江苏豪森药业集团有限公司 达格列净中间体的晶型及其制备方法
US20190309004A1 (en) 2016-10-13 2019-10-10 Boehringer Ingelheim International Gmbh Process for preparing glucopyranosyl-substituted benzyl-benzene derivatives
EA201990951A1 (ru) 2016-10-19 2019-11-29 Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
CA3039745A1 (en) 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN108285439B (zh) * 2017-01-09 2023-05-02 江苏天士力帝益药业有限公司 一种碳糖苷类钠葡萄糖转运蛋白体2抑制剂
WO2018163194A1 (en) * 2017-03-10 2018-09-13 Msn Laboratories Private Limited, R&D Center A process for the preparation of d-glucitol, 1,5-anhydro-1-c-[4-chloro-3-[[4- [[(3s)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, ( 1 s)
CN116036112A (zh) 2017-03-14 2023-05-02 吉利德科学公司 治疗猫冠状病毒感染的方法
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제
WO2018204198A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2018207111A1 (en) 2017-05-09 2018-11-15 Piramal Enterprises Limited A process for the preparation of sglt2 inhibitors and intermediates thereof
ES2958820T3 (es) 2017-06-05 2024-02-15 Laurus Labs Ltd Nuevo procedimiento para la preparación de empagliflozina o sus cocristales, solvatos y sus polimorfos
CN107163092B (zh) * 2017-06-13 2020-05-19 杭州科巢生物科技有限公司 Sglt-2糖尿病抑制剂及其中间体的制备方法
EP3649142A4 (en) * 2017-07-04 2021-09-01 Intocell, Inc. JOINTS WITH SPLITABLE LINKER AND USES THEREOF
EP4512475A3 (en) 2017-07-11 2025-05-14 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
MY210547A (en) 2017-11-30 2025-09-30 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
WO2019170543A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
CN111989103A (zh) 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
CZ2018188A3 (cs) 2018-04-18 2019-10-30 Zentiva, K.S. Částice s obsahem amorfního empagliflozinu, způsob jejich přípravy a farmaceutický přípravek
CN110117300A (zh) * 2018-04-23 2019-08-13 中国科学院成都生物研究所 包含钠-葡萄糖协同转运蛋白1抑制剂的药物用途
CN108610385A (zh) * 2018-04-23 2018-10-02 中国科学院成都生物研究所 一种钠-葡萄糖协同转运蛋白1抑制剂的药物用途
KR102204439B1 (ko) 2018-05-14 2021-01-18 에이치케이이노엔 주식회사 Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
CN108774275A (zh) * 2018-07-16 2018-11-09 西北大学 一步合成全乙酰基-α-O-苄基糖的方法
WO2020016335A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2020020896A1 (en) 2018-07-25 2020-01-30 Boehringer Ingelheim International Gmbh Empagliflozin for use in treating alport syndrome
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
JPWO2020050361A1 (ja) * 2018-09-06 2021-08-30 株式会社トクヤマ β−Ｃ−アリールグリコシド誘導体の製造方法
US20210388016A1 (en) * 2018-10-26 2021-12-16 Janssen Pharmaceutica Nv Glucopyranose derivatives useful as sglt2 inhibitors
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
SG11202102440SA (en) 2018-10-29 2021-04-29 Boehringer Ingelheim Int Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
WO2020242253A1 (ko) * 2019-05-30 2020-12-03 동아에스티 주식회사 Sglt-2 억제제인 신규 엠파글리플로진 유도체
CN112047915B (zh) * 2019-06-05 2023-02-17 北京惠之衡生物科技有限公司 C-糖苷类衍生物新的制备工艺
US20220324897A1 (en) * 2019-07-05 2022-10-13 Shandong Danhong Pharmaceutical Co., Ltd. Crystal form of sglt inhibitor and application thereof
MX2022001029A (es) * 2019-07-26 2022-05-24 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Inhibidor de sglts/dpp4 y aplicación del mismo.
CN114727624A (zh) 2019-11-28 2022-07-08 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂在非人哺乳动物的停奶中的用途
EP4076402A1 (en) 2019-12-19 2022-10-26 KRKA, d.d., Novo mesto Dosage form comprising amorphous solid solution of empagliflozin with polymer
KR102111248B1 (ko) 2019-12-30 2020-05-14 유니셀랩 주식회사 새로운 엠파글리플로진의 공결정
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
KR20220143732A (ko) 2020-02-17 2022-10-25 베링거잉겔하임베트메디카게엠베하 고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
CN115209894B (zh) 2020-03-06 2025-05-02 弗特克斯药品有限公司 治疗apol-1依赖性局灶节段性肾小球硬化的方法
CN118994170A (zh) 2020-03-12 2024-11-22 吉利德科学公司 制备1'-氰基核苷的方法
KR102207319B1 (ko) 2020-03-23 2021-01-25 유니셀랩 주식회사 새로운 엠파글리플로진의 공결정
KR102150825B1 (ko) 2020-04-06 2020-09-03 유니셀랩 주식회사 새로운 sglt-2 억제제의 신규한 공결정
EP4132651B1 (en) 2020-04-06 2026-03-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
WO2021204756A1 (en) 2020-04-07 2021-10-14 Boehringer Ingelheim International Gmbh Methods for the treatment of headache disorders
WO2021214023A1 (en) 2020-04-22 2021-10-28 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
WO2021250565A1 (en) * 2020-06-10 2021-12-16 Hikal Limited An improved process for preparation of empagliflozin and its crystalline polymorph
CA3187821A1 (en) 2020-06-24 2021-12-30 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
US11786540B2 (en) * 2020-07-10 2023-10-17 Rosalind Franklin University Of Medicine And Science Gliflozins and a method for their delivery during resuscitation from cardiac arrest to improve survival outcomes
AU2021202643B2 (en) 2020-07-27 2023-02-02 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
PT4188389T (pt) 2020-07-27 2025-10-07 Astrazeneca Ab Dapagliflozina para utilização em métodos de tratamento de doença renal crónica
WO2022047065A2 (en) 2020-08-27 2022-03-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
WO2022051316A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a sglt-2 inhibitor
KR20220068805A (ko) 2020-11-19 2022-05-26 한미약품 주식회사 신규한 글루코스 유도체
EP4023644A1 (en) 2020-12-30 2022-07-06 Zaklady Farmaceutyczne Polpharma SA Process for the preparation of a pharmaceutical agent
WO2022160737A1 (zh) * 2021-01-26 2022-08-04 东宝紫星(杭州)生物医药有限公司 四氢吡喃环类化合物的晶型及其制备方法
WO2022208172A1 (en) 2021-04-01 2022-10-06 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
MX2024001184A (es) 2021-07-28 2024-02-27 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
MX2024001185A (es) 2021-07-28 2024-02-27 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades renales en mamiferos no humanos.
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CN113773194B (zh) 2021-08-16 2023-05-02 浙江奥翔药业股份有限公司 作为降糖药合成原料的5-溴-2-氯-苯甲酸的制备方法
IL314031A (en) 2021-12-30 2024-09-01 Newamsterdam Pharma B V Obicetrapib and sglt2 inhibitor combination
CN118510504A (zh) 2022-01-26 2024-08-16 阿斯利康(瑞典)有限公司 用于在治疗糖尿病前期或降低发展2型糖尿病的风险中使用的达格列净
TW202525810A (zh) 2022-03-02 2025-07-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
EP4518847A1 (en) 2022-05-04 2025-03-12 Société des Produits Nestlé S.A. Ampk activator (cbda) and sglt2 inhibitor for metabolic health
US20250320199A1 (en) 2022-05-12 2025-10-16 Zhejiang Huahai Pharmaceutical Co., Ltd. Method for preparing glucopyranosyl-containing compound
EP4531810A1 (en) 2022-05-25 2025-04-09 Boehringer Ingelheim Vetmedica GmbH Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
WO2024033288A1 (en) 2022-08-12 2024-02-15 Société des Produits Nestlé S.A. Salicin derivatives as inhibitors of sglt2
WO2024033287A1 (en) 2022-08-12 2024-02-15 Société des Produits Nestlé S.A. Hydroxycholest-5-ene glycosides as inhibitors of sglt2
AU2023327691A1 (en) 2022-08-18 2025-01-16 Société des Produits Nestlé S.A. Methylated phloretin analogs as inhibitors of sglt2
WO2024056498A1 (en) 2022-09-12 2024-03-21 Société des Produits Nestlé S.A. Oxindole alkaloid derivatives as inhibitors of sglt2
WO2024068511A1 (en) 2022-09-28 2024-04-04 Société des Produits Nestlé S.A. Diterpenoid derivatives as inhibitors of sglt2
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
EP4378455A1 (en) 2022-11-29 2024-06-05 Sanovel Ilac Sanayi Ve Ticaret A.S. A pharmaceutical formulation comprising empagliflozin
CN115772163B (zh) * 2022-12-09 2025-07-22 中国科学院成都生物研究所 吲哚糖苷类化合物及吡咯糖苷类化合物及合成方法与应用
EP4420658A1 (en) 2023-02-24 2024-08-28 Sanovel Ilac Sanayi Ve Ticaret A.S. A film coated tablet comprising empagliflozin
US20240307628A1 (en) 2023-03-06 2024-09-19 Boehringer Ingelheim Vetmedica Gmbh Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
EP4442252A1 (en) 2023-04-04 2024-10-09 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet formulation of a solid dispersion comprising empagliflozin
EP4442253A1 (en) 2023-04-04 2024-10-09 Sanovel Ilac Sanayi Ve Ticaret A.S. A film coated tablet comprising empagliflozin and surfactant
EP4442254A1 (en) 2023-04-04 2024-10-09 Sanovel Ilac Sanayi Ve Ticaret A.S. Film coated tablets comprising empagliflozin
EP4701626A1 (en) 2023-04-24 2026-03-04 NewAmsterdam Pharma B.V. Amorphous obicetrapib and sglt2 inhibitor combination
KR20260019532A (ko) 2023-05-24 2026-02-10 베링거잉겔하임베트메디카게엠베하 하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
KR20250007816A (ko) 2023-07-06 2025-01-14 주식회사 경보제약 엠파글리플로진 ２ｌ­프롤린의 신규 결정형 및 이의 제조방법
WO2025125513A1 (en) 2023-12-15 2025-06-19 AstraZeneca Ireland Limited Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension
WO2025191117A1 (en) 2024-03-15 2025-09-18 Inventiva Prevention of blood disorders in patient treated with a ppar agonist
WO2025224069A1 (en) 2024-04-23 2025-10-30 Bayer Aktiengesellschaft Co-crystals of finerenone, pecavaptan, and sglt2 inhibitors

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL167151C (nl) * 1971-04-09 1981-11-16 Acf Chemiefarma Nv Werkwijze ter bereiding van geneesmiddelen met anti-parasitaire werking op basis van halogeen bevatten- de 2,2'-methyleendifenolderivaten, alsmede werkwijze ter bereiding van deze geneeskrachtige verbindingen.
JPS5639056A (en) * 1980-07-16 1981-04-14 Kanebo Ltd Preparation of n,n,n',n'-tetraacylated nucleus halogenated aromatic diamine
JPS58164502A (ja) 1982-03-26 1983-09-29 Chugai Pharmaceut Co Ltd 除草用組成物
US4786755A (en) 1985-06-03 1988-11-22 Warner-Lambert Company Diphenic acid monoamides
US4602023A (en) 1985-06-03 1986-07-22 Warner-Lambert Company Diphenic acid monoamides
US4786023A (en) * 1987-08-19 1988-11-22 Harris Leverett D Drafting implement holder
AU6024998A (en) 1997-01-15 1998-08-07 Glycomed Incorporated Aryl c-glycoside compounds and sulfated esters thereof
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
JPH11124392A (ja) 1997-10-21 1999-05-11 Sankyo Co Ltd Ｃ−グリコシル化されたアリールスズ化合物
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja) 2000-02-02 2010-04-28 壽製薬株式会社 Ｃ−配糖体を含有する薬剤
US7465712B2 (en) * 2000-03-17 2008-12-16 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
DE60122193T2 (de) 2000-09-29 2007-07-05 Kissei Pharmaceutical Co., Ltd., Matsumoto Glucopyranosyloxybenzylbenzol derivate und medizinische zusammensetzungen, die diese verbindungen enthalten
AU2002223127A1 (en) 2000-11-30 2002-06-11 Kissei Pharmaceutical Co., Ltd. Intellectual Property Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
TWI255817B (en) * 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
ES2258141T3 (es) 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
WO2003031458A1 (en) * 2001-10-12 2003-04-17 Dana-Farber Cancer Institute Methods for synthesis of diarylmethanes
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
AU2003299966A1 (en) 2003-01-03 2004-08-10 Bristol-Myers Squibb Company Methods of producing c-aryl glucoside sglt2 inhibitors
US7164015B2 (en) 2003-02-27 2007-01-16 Bristol-Myers Squibb Company Non-cryogenic process for forming glycosides
CN1802366B (zh) 2003-03-14 2010-12-22 安斯泰来制药有限公司 C-糖苷衍生物及其盐
CN1835962A (zh) * 2003-06-03 2006-09-20 加利福尼亚大学董事会 利用乙酰化二糖治疗疾病的组合物与方法
JP2004359630A (ja) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd ジフルオロジフェニルメタン誘導体及びその塩
MXPA06001274A (es) 2003-08-01 2006-04-11 Tanabe Seiyaku Co Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
AU2004261660A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic C-glycosides
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
WO2005085237A1 (ja) 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
RU2387663C2 (ru) 2004-03-04 2010-04-27 Киссеи Фармасьютикал Ко., Лтд. Конденсированные гетероциклические производные, содержащие их медицинские композиции и их медицинское применение
EP2360165A3 (de) * 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1773800A1 (de) 2004-07-27 2007-04-18 Boehringer Ingelheim International GmbH D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006064033A2 (en) 2004-12-16 2006-06-22 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2006089872A1 (en) 2005-02-23 2006-08-31 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
ATE453656T1 (de) 2005-04-15 2010-01-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) * 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (en) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
ES2346347T3 (es) 2005-07-27 2010-10-14 Boehringer Ingelheim International Gmbh Derivados de ((hetero)cicloalquiletinil-bencil)-benceno y su uso como inhibidores del cotransportador de glucosa dependiente de sodio (sglt).
ATE484499T1 (de) 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
CN101238112A (zh) 2005-09-08 2008-08-06 贝林格尔·英格海姆国际有限公司 1-氯-4-(β-D-吡喃葡萄糖-1-基)-2-(4-乙炔基-苄基)-苯的晶形、其制备方法及其用于制备药物中的用途
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AU2007216452A1 (en) 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
CA2656847A1 (en) * 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
US7858587B2 (en) * 2006-09-21 2010-12-28 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture
EP2086991A1 (en) * 2006-10-27 2009-08-12 Boehringer Ingelheim International GmbH CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
US7879806B2 (en) * 2006-11-06 2011-02-01 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture
EP2081569A2 (en) * 2006-11-09 2009-07-29 Boehringer Ingelheim International GmbH Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
EP2382972A1 (en) * 2007-01-26 2011-11-02 Boehringer Ingelheim International GmbH Methods for preventing and treating neurodegenerative disorders
JP2010519273A (ja) * 2007-02-21 2010-06-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 四置換グルコピラノシル化ベンゼン誘導体、このような化合物を含む薬物、それらの使用及びそれらの製造方法
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
WO2009117836A1 (en) * 2008-03-28 2009-10-01 Quanser Consulting Inc. Drill assembly and method to reduce drill bit plunge
MY161472A (en) * 2009-02-13 2017-04-14 Boehringer Ingelheim Int Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
MX345494B (es) * 2009-02-13 2017-02-02 Boehringer Ingelheim Int Gmbh * Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, dosificación farmacéutica de la misma, procesos para su preparación y usos de la misma para el control glucemico mejorado en un paciente.
PL2395983T3 (pl) * 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
BR112012007085B8 (pt) * 2009-09-30 2021-05-25 Boehringer Ingelheim Int processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila

Also Published As

Publication number Publication date
JP5147314B2 (ja) 2013-02-20
JP4181605B2 (ja) 2008-11-19
HRP20120627T1 (hr) 2012-08-31
CN103467423A (zh) 2013-12-25
EP2360165A3 (de) 2012-01-04
CY2014042I2 (el) 2015-12-09
CN103450129A (zh) 2013-12-18
RS52365B (sr) 2012-12-31
EP1730131B1 (de) 2012-05-09
HK1188775A1 (zh) 2014-05-16
AR077513A2 (es) 2011-08-31
EP2360164A2 (de) 2011-08-24
JP2007522143A (ja) 2007-08-09
BE2014C064I2 (cs) 2024-08-08
SI1730131T1 (sl) 2012-08-31
IL218714A (en) 2013-02-28
DK1730131T3 (da) 2012-08-13
NZ550464A (en) 2010-10-29
AU2005225511B2 (en) 2009-01-08
NO335264B1 (no) 2014-10-27
LTC1730131I2 (lt) 2025-03-25
ATE557013T1 (de) 2012-05-15
EP2295422A3 (de) 2012-01-04
CN103435581A (zh) 2013-12-11
PT1730131E (pt) 2012-06-15
US20110178033A1 (en) 2011-07-21
WO2005092877A8 (de) 2006-01-26
NO2014028I2 (no) 2016-08-01
EP2360165A2 (de) 2011-08-24
EA011158B1 (ru) 2009-02-27
CN103030617A (zh) 2013-04-10
CA2557801C (en) 2013-06-25
CN103435581B (zh) 2015-08-19
IL177043A (en) 2013-03-24
CN103467423B (zh) 2016-03-16
CA2557801A1 (en) 2005-10-06
US20140046046A1 (en) 2014-02-13
NO20140127L (no) 2006-12-13
US20120296080A1 (en) 2012-11-22
CY2014042I1 (el) 2015-12-09
IL177043A0 (en) 2006-12-10
MY151336A (en) 2014-05-15
BRPI0508830B1 (pt) 2018-06-12
JP2007246544A (ja) 2007-09-27
TW200538463A (en) 2005-12-01
PL1730131T3 (pl) 2012-10-31
NO2014028I1 (no) 2014-11-17
SG151271A1 (en) 2009-04-30
CY1112948T1 (el) 2015-12-09
HUS1400056I1 (hu) 2016-08-29
FR14C0074I1 (cs) 2014-10-31
LU92555I9 (cs) 2019-01-15
US20090326215A1 (en) 2009-12-31
BRPI0508830A (pt) 2007-08-14
HK1188776A1 (en) 2014-05-16
HK1188777A1 (en) 2014-05-16
ES2387881T3 (es) 2012-10-03
AR048041A1 (es) 2006-03-22
EA200601584A1 (ru) 2007-04-27
AR077512A2 (es) 2011-08-31
EP2295422A2 (de) 2011-03-16
KR101174726B1 (ko) 2012-08-17
EP2360164A3 (de) 2012-01-04
AU2005225511C1 (en) 2023-04-13
ME01422B (me) 2013-12-20
IL218714A0 (en) 2012-05-31
TWI323264B (en) 2010-04-11
US20050209166A1 (en) 2005-09-22
LTPA2014035I1 (lt) 2014-10-27
US7579449B2 (en) 2009-08-25
NO20064201L (no) 2006-12-13
EP1730131A1 (de) 2006-12-13
US20090023913A1 (en) 2009-01-22
ECSP066855A (es) 2006-11-24
LU92555I2 (fr) 2014-11-24
KR20120007088A (ko) 2012-01-19
WO2005092877A1 (de) 2005-10-06
JP5147469B2 (ja) 2013-02-20
KR20060133021A (ko) 2006-12-22
AU2005225511A1 (en) 2005-10-06
CN103450129B (zh) 2015-08-12
BRPI0508830B8 (pt) 2021-05-25
JP2008208127A (ja) 2008-09-11

Similar Documents

Publication Publication Date Title
IL282138B1 (en) Process for preparing purified drug conjugates
HUS1400056I1 (hu) Glükopiranozil-helyettesített benzol-származékok, az említett vegyületeket tartalmazó gyógyszerek, azok alkalmazása, és eljárás elõállításukra
SI2084172T1 (sl) Novi z benzilnimi ostanki substituirani 1,4-benzotiepin-1,1-dioksidni derivati, postopek za njihovo izdelavo, te spojine vsebujoča zdravila in njihova uporaba
IL205759A (en) History of isoxazolo-pyridine, a process for their preparation and the drugs containing them
EP2143792A4 (en) Single-stranded cyclic RNA and method of production thereof
ATE460401T1 (de) 1,2,4,5-tetrahydro-3h-benzazepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
IL188606A0 (en) Novel 1,4-benzothiazepine-1,1-dioxide, derivative having improved properties, method for the production thereof, medicaments containing said compound, and use thereof
WO2008077557A8 (en) 8-ethinylxanthine derivatives as selective a2a receptor antagonists
BRPI0811712A2 (pt) "composto, processo de preparação de um composto e composição farmacéutica".
PL1896389T3 (pl) Sposób otrzymywania dronabinolu z kannabidiolu z zastosowaniem sita molekularnego
FR2934596B1 (fr) Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
IL176913A0 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
HUP0500170A3 (en) Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
IL179758A0 (en) Substituted tetrahydro - 2h - isoquinolin - 1 - one derivatives, method for the production thereof, and use of the same as medicaments
EP2292242A4 (en) SCUTELLARINE DERIVATIVE, PRODUCTION PROCESS, PHARMACEUTICAL COMPOSITION, AND ITS USE
FR2919200B1 (fr) Procede de cristallisation en continu
WO2009055289A3 (en) Therapeutic substituted lactams
FR2925047B1 (fr) Procede de preparation de composes p-hydroxymandeliques eventuellement substitues et derives.
IL190596A0 (en) 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
MA29089B1 (fr) Procede de fabrication de composes organiques
FR2842524B1 (fr) Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
FR2873372B1 (fr) Procede de preparation de derives n-piperidino-1,5- diphenylpyrazole-3-carboxamide
AP2007004223A0 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
FR2842526B1 (fr) Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
EP2371819A4 (en) NOVEL QUINOLINE DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF, METHOD OF USING THESE DERIVATIVES IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM